Europe
Oxurion NV announces that it has enrolled the first patient in a Phase 2 open-label multi-centre study evaluating the efficacy and safety of intravitreal THR-317
CHF 400 million investment in Lonza’s biopark in Visp (CH) to expand IbexTM Solutions with two innovative offerings
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
LineaRx, a subsidiary of Applied DNA Sciences, has entered into a Joint Development Agreement with Takis SRL and Evvivax SLR. They will focus on developing anti-cancer vaccines.
NOXXON Pharma N.V. announced today that the previously disclosed convertible bonds (see press releases of June 15 and August 1, 2018) have been listed on the Euronext Access market in Paris as notes convertible into NOXXON shares
Optibrium, Intellegens and Medicines Discovery Catapult awarded funding to apply machine learning in drug discovery
New modular continuous processing pilot plant in Germany
Top-line data from NOX-A12 monotherapy trial plus available safety data from NOX-A12 / Keytruda® combination trial to be presented
Poietis and Prometheus, entered into a 2-years Collaborative Research Agreement focused on high-precision 3D Bioprinting of tissue engineered Advanced Therapeutic Medicinal Products (ATMPs) for skeletal regeneration.
Additional clinical trial data for prophylaxis of HAE requested
PRESS RELEASES